Moderna
Search results
BioNTech. We are a global immunotherapy powerhouse aspiring to translate science into survival. Read more. Interest Selector. Our mission. We are committed to improving the health of people worldwide with our fundamental research and development of immunotherapies. We believe in scientific rigor, innovation and passion as driving force.
BioNTech SE (/ b iː ˈ ɒ n t ɛ k / bee-ON-tek; or / b aɪ ˈ ɒ n t ɛ k / bye-ON-tek short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases.
Vision & Mission. A transatlantic leader in individualized neoantigen-targeted T cell therapies. Based in Cambridge, MA, BioNTech US serves as BioNTech’s North American headquarters and is an important part of our global effort to pioneer the development of next-generation immuno-oncology therapies.
6 days ago · BioNTech also expects new private markets to open up in places like the United Kingdom this year, Richardson noted. For the full year, BioNTech is sticking by its revenue forecast of 2.5 billion ...
5 days ago · BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, May 6, 2024, at 8:00 a.m. EDT (2:00 p.m. CEST) to report its financial ...
Dec 11, 2020 · 2024. Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older. Monday, August 23, 2021 - 11:57am. View pdf copy Copy to clipboard Open in tab. COMIRNATY is the first COVID-19 vaccine to be granted FDA approval.
Oct 26, 2023 · NEW YORK & MAINZ, GERMANY-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study ( NCT05596734) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of ...
